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Activated Protein C Protects Myocardium Via Activation of  
Anti-apoptotic Pathways of Survival in Ischemia-reperfused  
Rat Heart 
Activated protein C (APC) is known to be beneficial on ischemia reperfusion injury in 
myocardium. However, the protection mechanism of APC is not fully understood. The 
purpose of this study was to investigate the effects and possible mechanisms of APC on 
myocardial ischemic damage. Artificially ventilated anaesthetized Sprague-Dawley rats 
were subjected to a 30 min of left anterior descending coronary artery occlusion followed 
by 2 hr of reperfusion. Rats were randomly divided into four groups; Sham, I/R, APC 
preconditioning and postconditioning group. Myocardial infarct size, apoptosis index, the 
phosphorylation of ERK1/2, Bcl-2, Bax and cytochrome c genes and proteins were assessed. 
In APC-administrated rat hearts, regardless of the timing of administration, infarct size was 
consistently reduced compared to ischemia/reperfusion (I/R) rats. APC improved the 
expression of ERK1/2 and anti-apoptotic protein Bcl-2 which were significantly reduced in 
the I/R rats. APC reduced the expression of pro-apoptotic genes, Bax and cytochrome c. 
These findings suggest that APC produces cardioprotective effect by preserving the 
expression of proteins and genes involved in anti-apoptotic pathways, regardless of the 
timing of administration.  
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Cardiovascular Disorders
INTRODUCTION
Myocardial ischemia-reperfusion injury (MIRI) is a complex 
pathophysiological event, resulting in serious acute and chron-
ic heart damage. Although the precise mechanism responsible 
for MIRI remains unclear, it is widely accepted that apoptotic 
cell death is involved in the development of ischemic heart dam-
age. Activated protein C (APC) is an important physiological 
anticoagulant that is produced from protein C by the action of 
the thrombin–thrombomodulin complex on endothelial cells 
(1). APC plays a significant role in the regulation of anti-inflam-
matory processes by inhibiting cytokine production by mono-
cytes and has been reported to attenuate tissue or organ injury 
in various pathological conditions (2-5). It has been well dem-
onstrated that APC can reduce hypoxia-induced apoptosis in 
neuron and cerebral endothelial cells (2). In myocardial isch-
emia, APC has been reported to have beneficial effects in isch-
emia-reperfusion injury with its inhibitory effects on the myo-
cardial apoptosis and inflammation (1). 
  Apoptosis is a crucial event in various physiologic processes, 
such as embryogenesis, organ development, and cell prolifera-
tion, as well as in pathologic processes, which contributes sig-
nificantly to post-ischemic cardiomyocyte death (6). But there 
are no evidence regarding the effect of activated protein C on 
anti-apoptotic pathways in ischemia/reperfusion (I/R) injury. 
In mammalian cells, among three major mitogen activated pro-
tein kinases (MAPKs) signaling pathways, activation of extracel-
lular signal related protein kinases (ERK1/2) exerts beneficial 
effect on post-ischemic myocardial apoptosis (7). Thus, we eval-
uated the effects of activated protein C against I/R injury on myo-
cardial infarction in rat in terms of the expression of proteins in-
volved in apoptosis signaling cascades.
 
MATERIALS AND METHODS
Animals 
Male Sprague–Dawley (SD) rats (SPF grade, 220-250 g) were 
purchased from Tongji Medical School, Huazhong University of 
Science and Technology (HUST), China. Animals were main-
tained under standard laboratory conditions at 25±2°C, relative 
humidity of 50±15%, and normal photoperiod (12 hr dark and 
12 hr light). The procedures for experiments and animal care were 
approved by the institutional animal care and use committee of 
HUST (approval number: 2004-0007), and conformed to the 
guide for the care and use of laboratory animals by the National 
Institutes of Health (NIH Publication No. 80-23).Ding J-W, et al.  •  Activated Protein C Protects Cardiomyocytes Apoptosis
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Drugs and preconditioning
APC was purchased from Sigma-Aldrich (Oakvile, ON, Canada), 
and dissolved in distilled water on the day of administration. 
The 48 rats were randomly divided into four groups: the sham 
operation group (sham); I/R group (I/R); APC-preconditioning 
group (Pre-APC) and APC-postconditioning group (Post-APC). 
In the sham operation and I/R groups, 0.9 percent saline solu-
tion (2 mL/kg) was injected 5 min prior to the reperfusion pro-
tocol. In APC-preconditioning group, APC (2 mg/kg) was given 
also 5 min prior to the reperfusion protocol. In APC-postcondi-
tioning group, APC was administrated 5 min after reperfusion.
Experimental protocol 
The rats were anesthetized with an intraperitoneal injection of 
pentobarbital sodium (30 mg/kg). After endotracheal intubation, 
ventilation was provided by a rodent respirator at a respiratory 
rate of 50/min with a tidal volume of 20 mL/kg body weight (8). 
A left parasternal incision was made through the third and fourth 
ribs, and the pericardium was gently opened to expose the heart. 
The lateral anterior descending artery (LAD) was ligated using a 
6-0 silk suture. Additionally, a medical latex tube (socket, inner 
diameter, 1.5 mm) was placed between the ligature and the LAD. 
Myocardial ischemia was induced by compressing the LAD by 
tightening the ligature around the latex tube. The ECG was mon-
itored for changes in the ST-T segment caused by tightening or 
loosing the ligation. After 30-min ischemia, the latex tube was 
removed to reperfuse the myocardium by restoring the coronary 
circulation. After 2-hr reperfusion, rats were killed, and parts of 
the anterior wall of the left ventricular myocardium near the 
cardiac apex were obtained for further analysis. The sham con-
trol group underwent the same procedures, with the exception 
of the induction of myocardial ischemia/reperfusion.
Hemodynamic measurements
We assessed cardiac hemodynamic function in vivo. The right 
common carotid artery of rat was isolated and cannulated with 
a 2-Fr micromanometer. Left ventricular (LV) pressure and LV 
end-diastolic pressure (LVEDP) were measured by the catheter 
advanced into the LV cavity, and data were recorded and ana-
lyzed. These parameters as well as LV maximum positive change 
in pressure over time (+dP/dtmax), as a measure of cardiac con-
tractility, and LV minimum negative change in pressure over 
time (–dP/dtmin), as a measure of relaxation, were recorded at 
baseline and after administration of APC.
Determination of LV area at risk and infarct size
At the end of the perfusion protocols, the coronary artery was 
reoccluded and 4 mL of 0.1% Evans blue dye was injected into 
the aorta to delineate the zone at risk. Stained hearts were fro-
zen, sliced, and incubated at 37°C in 1% triphenyltetrazolium 
chloride to delineate the infarcted tissue. Slices were then fixed 
and quantified by planimetry using the computer-based image 
analyzer SigmaScan Pro 5.0 (SPSS Science, Chicago, IL, USA). 
Infarct size was expressed as a percentage of the area at risk zone. 
The area at risk was calculated as a percentage of the total ven-
tricular area (9). 
Immunoblot analysis 
LV specimens were pulverized and dissolved in lysis buffer. The 
solution was vigorously homogenized and centrifuged at 12,000 g 
for 10 min at 4°C. The supernatant was separated in a 12% SDS-
polyacrylamide gel and transferred to PVDF membrane. After 
blocking the membrane with Tris-buffered saline-Tween 20 (TBS-
T, 0.1% Tween 20) containing 5% non-fat dried milk for 1 hr at 
room temperature, membranes were washed twice with TBS-T 
and incubated with primary antibodies for 1 hr at room temper-
ature or for overnight at 4°C. The following primary antibodies 
were used: rabbit anti-extracellular signal-regulated kinases 
(ERK1/2), mouse anti-phospho ERK1/2 and mouse anti-β actin 
antibodies (Sigma, St. Louis, MO, USA). The membranes were 
washed three times with TBS-T for 10 min, and then incubated 
for 1 hr at room temperature with horseradish peroxidase (HRP)-
conjugated secondary antibodies. After extensive washing, the 
bands were visualized by an enhanced chemiluminescence 
system (10). 
RT-PCR analysis 
The total RNA from the cardiac muscle samples was extracted 
and puriﬁed using the Trizol reagent kit (Invitrogen, CA, USA). 
Total RNA was reversely transcribed into complementary DNA 
(cDNA) using the cDNA synthesis kit (Takara Bionic, Otsu, Japan) 
according to the manufacturer’s protocol. The opticon-2 real-
time PCR reactor (MJ Research, Fremont, CA, USA) and real-
time PCR kit (SYBR Premix Ex TaqTM, TaKaRa, Japan) were em-
ployed based on the manufacturer’s instruction. A 20 µL reverse 
transcription reaction mixture was incubated at 42°C for 15 min, 
heated to 95°C for 2 min. The PCR condition was at 95°C for 10 
sec, then 40 cycles of 95°C for 5 sec, and 60°C for 30 sec and 72°C 
for 1 min. GAPDH and β-actin were used as the housekeeping 
genes. The mRNA levels were calculated based on the method 
of 2-
ΔΔCt (11, 12). The primers were as follows: Bax, sense primer 
5´-AGACACCTGAGCTGACCTTGGAG-3´, antisense primer 
5´-GTTGAAGTTGCCATCAGCAAACA-3´. Bcl-2, sense primer 
5´-TGAACCGGCATCTGCACAC-3´, antisense primer 5´-CGT- 
CTTCAGAGACAGCCAGGAG-3´. cytochrome c, sense primer 
5´-CATAAGACTGGACCAAACC-3´, antisense primer 5´-TCT-
GCCCTTTCTCCCT-3´. β-actin, sense primer 5´-GTCCCTCA- 
CCCTCCCAAAAG-3´, antisense primer 5´-GCTGCCTCAACA- 
CCTCAACCC-3´. GAPDH, sense primer 5´-ACCACAGTCCAT-
GCCATCAC-3´ and antisense primer 5´-TCCACCACCCTGTT-
GCTGTA-3´. Ding J-W, et al.  •  Activated Protein C Protects Cardiomyocytes Apoptosis
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Immunohistochemistry analysis
The myocardial tissues were ﬁxed with 10% neutral-buffered 
formalin, dehydrated in increasing concentrations of ethanol, 
embedded in parafﬁn, and sectioned into 4-μm slices. After de-
paraffinization, the sections were immersed in 3% hydrogen 
peroxide in methanol for 30 min, placed in a 500-W microwave 
for 5 min and incubated with normal goat serum for 10 min. 
The primary antibody was diluted appropriately and incubated 
with the sections overnight at 4°C. Biotinylated secondary anti-
body was added followed by the addition of HRP-Streptavidin 
complex, and then the sections were stained with DAB solution 
and counterstained with hematoxylin. Brown immunoprecipi-
tates occurred in positive cytoplasm after staining. In immuno-
histochemical analysis of quantity, ﬁve random microscopic 
ﬁelds from each section were examined at ×400 magnification 
with a micro-image collecting system. The average grey values 
were analyzed using LEICA Q55OIW image analysis software. 
Determination of myocardial apoptosis
Myocardial tissue samples were obtained at the end of the reper-
fusion, fixed in 10% paraformaldehyde, paraffin-embedded, and 
sectioned. TUNEL staining was performed in deparaffinized 
and rehydrated sections according to the demands of TUNEL 
assay kit. After TUNEL staining, the sections were counterstained 
with hematoxylin. Total cardiomyocytes and TUNEL positive 
cells in the specimens were counted under light microscopic 
analysis. Five high-power fields (×400) of each section were ran-
domly selected from the marginal and the central parts of the 
ischemic zone. The ratio of TUNEL-positive cells to total cardio-
myocytes was apoptosis index (AI).
Statistical analysis  
Quantitative data were expressed as mean±SD. For experiments 
with three or more groups of animals, one-way analysis of vari-
ance (ANOVA) was performed, and Student–Newman–Keuls 
(SNK)-qtest was used for selected groups. A P value of less than 
0.05 was considered as statistically significant. Analysis was car-
Fig. 1. The changes of the hemodynamic parameters before and during myocardial I/R. (A) Left ventricular end-diastolic pressure (LVEDP) during ischemia-reperfusion injury. (B) 
Left ventricular developed pressure (LVDP). (C) Contractility (+dP/dt) during ischemia-reperfusion injury. dP/dtmin during ischemia-reperfusion injury. (D) Compliance (-dP/dt) 
during ischemia-reperfusion injury. All values are means±SE (n=6). 
*P<0.05 for Pre-APC and Post-APC vs the I/R group.
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ried out using Statistical Product and Service Solutions (SPSS 
11.0).
  Student–Newman–Keuls (SNK)-qtest is a kind of method to 
made multiple comparison.
  Statistical Product and Service Solutions (SPSS11.0) is Statis-
tical software.
RESULTS
The effects of APC on cardiac function
Parameters were studied both at baseline and in response to APC 
administration and included LVDP, LVEDP, and LV+dP/dtmax 
and LV–dP/dtmin as measures of ventricular contractility and re-
laxation, respectively. Rats undergoing I/R had significantly im-
paired LV contractile function. Treatment with APC significant-
ly preserved impaired LV contractility and relaxation. Obviously 
improvements in LV +dP/dtmax and LV –dP/dtmin were also seen 
in animals treated with APC. No differences existed in LVEDP, 
LVDP, +dP/dt, and –dP/dt between the APC groups during isch-
emia and reperfusion (Fig. 1).
The effects of APC on infarct size 
Mean infarct size of the AAR in the I/R group was 58.7±3.1%. In 
the groups administered with APC, infarct sizes were signifi-
cantly reduced to 31.4±2.6% and 28.4±2.8% in the Pre-APC and 
Post-APC group, respectively (all P<0.01). No significant differ-
ences were observed between the APC-administrated groups 
(Fig. 2).
Western blotting analysis 
Western blot analysis of ERK1/2 is shown in Fig. 3. I/R injury 
obviously increased P-ERK1/2 expression (3.4±0.21; respective-
ly) compared to the sham as measured densitometrically (fold 
relative to sham). In contrast to the I/R group, APC treatment 
significantly increased P-ERK1/2 expression (7.45±0.34 vs 3.4± 
0.21, P<0.01 and 6.98±0.31 vs 3.4±0.21, P<0.01). Phosphoryla-
tions of ERK1/2 were similar between the APC-administrated 
groups (Fig. 3).
The expression of Bax, Bcl-2 and cytochrome c
Expression levels of pro-apoptotic proteins, Bax and cytochrome 
c, significantly increased and expression level of anti-apoptotic 
protein, Bcl-2 significantly decreased in the I/R group than in 
the sham group. In the APC-administrated groups, the expres-
sion of Bax and cytochrome c significantly decreased and the 
  Sham  I/R  Pre-APC  Post-APC
*
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*
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Fig. 2. The effect of APC on infarct size. Infarct size is expressed as a percentage of 
the area at risk in rats, which was reduced by APC administration. Mean±SE, n=6. 
*P<0.01 vs sham group; 
†P<0.01 vs I/R group.
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Fig. 3. Effect of APC treatment on p-ERK protein in rat heart after 30 min ischemia 
and 2 h reperfusion. The phosphorylation was quantified by densitometry using image 
analysis program. Mean±SE, n=6. 
*P<0.01 vs sham; 
†P<0.01 vs I/R.
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Fig. 4. The effect of APC on expressions of Bax, Bcl-2 and cytochrome C mRNA. All 
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Table 1. Effects of APC on the expressions of Bcl-2, Bax and cytochrome c 
Group Bcl-2 Bax Cytochrome c
Sham 0.352±0.069 0.244±0.025 0.176±0.032
I/R 0.741±0.043* 0.859±0.076* 0.899±0.097*
Pre-APC 0.973±0.103
† 0.546±0.041
† 0.541±0.073
‡
Post-APC 0.997±0.116
† 0.578±0.039
† 0.567±0.046
‡
Data are presented as mean±SE, n=6.
*P<0.01 vs sham group; 
†P<0.05 vs I/R group, 
‡P<0.01 vs I/R group.
I/R, ischemia/reperfusion; APC, activated protein C.Ding J-W, et al.  •  Activated Protein C Protects Cardiomyocytes Apoptosis
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expression level of Bcl-2 significantly increased than in the I/R 
group. The expression levels of Bax, cytochrome c and Bcl-2 were 
similar among the APC-administrated groups (Fig. 4, Table 1). 
TUNEL assay
A number of TUNEL-positive cells were observed in the myo-
cardium in the I/R group. Compared with I/R group, the apop-
tosis indeces were decreased significantly in APC-administrat-
ed groups (all P<0.01). No significant differences were observed 
between the APC-administrated groups (Fig. 5).
DISCUSSION
The current results confirm that APC significantly reduces myo-
cardial infarct size without reference to the timing of administra-
tion in I/R rat heart, which is in conjunction with the preserved 
phosphorylations of ERK1/2 and anti-apoptotic proteins, Bcl-2 
and attenuated pro-apoptotic proteins, Bax and cytochrome c 
resulting from I/R.
  Activated protein C (APC) is a serine protease with systemic 
anticoagulant activity, which is mediated by irreversible pro-
teolytic inactivation of factors Va and VIIIa with contributions 
by various cofactors (13). Independent of its anticoagulant ac-
tivity, APC exerts direct cellular effects that are mediated by the 
protein C cellular pathway resulting in the following: 1) cyto-
protective alteration of gene expression profiles, 2) antiinflam-
matory activities, 3) antiapoptotic activity, and 4) protection of 
endothelial barriers (14-16). In myocardial ischemia, APC has 
been reported to have beneficial effects in ischemia-reperfu-
sion injury with its inhibitory effects on the myocardial apopto-
sis and inflammation (1). However, little has been studied re-
garding mechanisms of APC induced cardioprotection and we 
could observe that APC acted through proteins involved in anti-
apoptoic pathways of survival regardless of timing of adminis-
tration. Apoptosis has been linked with reperfusion-induced 
myocardial injury after reversible coronary occlusion and sug-
gested as one of the key mechanisms in the development of in-
farction in rat cardiac myocytes (17, 18). 
  In the current study, APC increased the phosphorylation of 
ERK1/2 and anti-apoptotic proteins in I/R rat heart. ERK is acti-
vated in response to I/R, oxidative stress, and hypoxia, and is an 
established player in the anti-apoptotic defense network (7). As 
D
A B C
Fig. 5. Effect of APC on apoptosis in ischemic reperfusion-induced myocardial injury. Detection of apoptosis was done at 2 hr after reperfusion. (A) Sham group, (B) I/R group, (C) 
Pre-APC group, (D) Post-APC group. (E) Mean apoptotic index was counted in each group (A-D). TUNEL stain ×400 (n=6 animals per group). Arrow indicates TUNEL positive cells.
*P<0.05 vs sham group, 
†P<0.05 vs I/R group. 
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our results indicate, APC preserved the phosphorylation of ERK1/ 
2 which were significantly reduced following I/R leading to im-
proved viability of the rat heart exposed to I/R. In response to 
an apoptotic stimulus such as I/R, the pro-apoptotic protein, 
Bax, undergoes a conformational change that allows it to trans-
locate to the mitochondria, where it induces cytochrome c re-
lease. Once released, cytochrome c leads to the formation of the 
apoptosome, a complex comprised of apoptotic protease-acti-
vating factor-1 (Apaf-1), procaspase-9 and ATP, which permits 
the autoactivation of procaspase-9 that in turn facilitates cas-
pase-3 activation. Active caspase-3 activates the caspase acti-
vated DNase, leading to oligonucleosomal DNA fragmentation 
(19). Phosphorylation of ERK1/2 inhibits the conformational 
change in Bax protein and cytochrome c induced caspase acti-
vation, thereby preventing apoptosis (20). Bcl-2 normally resides 
in mitochondrial membranes and the cytoplasm, whose over-
expression is a potential mechanism for apoptotic resistance 
(21). The anti-apoptotic protein Bcl-2 attenuates cellular injury 
by inhibiting cytochrome c translocation and inhibits Bax trans-
location (22, 23). In this study, we could observe that improved 
phosphorylations of ERK1/2, and associated recovery of expres-
sion of Bcl-2 and mitigated expression of Bax and mitochondri-
al cytochrome c release against I/R induced injury, which all 
indicate APC induced a cardioprotective effect via anti-apopto-
sis pathways of survival in I/R rat heart. In addition, we have in-
vestigated the cardioprotective effects of APC with different ad-
ministration protocols, and we observed similar protective effect 
between APC pre- and post-conditioning groups. These results 
suggest that cardioprotective signaling pathways during the APC 
pre- and post-conditioning might be similar. 
  In conclusion, APC confers myocardial protection against in-
jury in I/R rat hearts without reference to the timing of admin-
istration, which is conducted with preserved phosphorylations 
of ERK1/2 and of signal transduction proteins against apoptotic 
cell death.
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